|
Sex
|
|
Male
|
23 (72%)
|
30 (70%)
|
1.00
|
|
Age (years)
|
65.7 (9.0)
|
63.1 (12.4)
|
0.33
|
|
Body weight (kg)
|
58.1 (10.0)
|
57.9 (9.0)
|
0.91
|
|
Body surface area (kg/m2)
|
1.62 (0.17)
|
1.60 (0.16)
|
0.59
|
|
Performance Status (ECOG)
|
|
0 / 1 / 2
|
15 (47%) / 16 (50%) / 1 (3%)
|
27 (63%) / 15 (35%) / 1 (2%)
|
0.39
|
|
Diabetes mellitus
|
8 (25%)
|
6 (14%)
|
0.25
|
|
Smoking status
|
|
Never / former / current
|
8 (25%) / 15 (47%) / 9 (28%)
|
17 (40%) / 16 (37%) / 10 (23%)
|
0.42
|
|
Serum albumin level (g/dl)
|
3.64 (0.66)
|
3.74 (0.36)
|
0.43
|
|
Primary origin of tumors
|
|
Rectal / colon / other
|
9 (28%) / 22 (69%) / 1 (3%)
|
22 (51%) / 18 (42%) / 3 (7%)
|
0.07
|
|
On the left side of the colon / on the right side of the colona
|
21 (66%) / 11 (34%)
|
33 (78%) / 10 (23%)
|
0.31
|
|
Line of treatment
|
|
1st / 2nd / 3rd
|
25 (78%) / 6 (19%) / 1 (3%)
|
38 (88%) / 4 (9%) / 1 (2%)
|
0.47
|
|
Combined regimen
|
|
FOLFOX / FOLFIRI / LV5FU
|
22 (69%) / 9 (28%) / 1 (3%)
|
38 (88%) / 4 (9%) / 1 (2%)
|
0.10
|
|
Concomitant bolus 5-FU
|
|
Presence / absence
|
32 (100%) / 0 (0%)
|
41 (95%) / 2 (5%)
|
0.50
|
|
Relative dose intensity in cycle 1 (%)
|
97.3 (7.8)
|
93.0 (21.6)
|
0.28
|
|
Cetuximab intervalb
|
|
Weekly / biweekly
|
-
|
13 (30%) / 30 (70%)
|
-
|
